Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $30.7 million.

  • Caribou Biosciences' Total Current Liabilities fell 12.75% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year decrease of 12.75%. This contributed to the annual value of $30.7 million for FY2024, which is 8.30% up from last year.
  • Latest data reveals that Caribou Biosciences reported Total Current Liabilities of $30.7 million as of FY2024, which was up 8.30% from $28.3 million recorded in FY2023.
  • In the past 5 years, Caribou Biosciences' Total Current Liabilities registered a high of $30.7 million during FY2024, and its lowest value of $12.4 million during FY2020.
  • For the 3-year period, Caribou Biosciences' Total Current Liabilities averaged around $29.0 million, with its median value being $28.3 million (2023).
  • Data for Caribou Biosciences' Total Current Liabilities shows a peak YoY soared of 108.48% (in 2021) over the last 5 years.
  • Over the past 5 years, Caribou Biosciences' Total Current Liabilities (Yearly) stood at $12.4 million in 2020, then soared by 108.48% to $25.8 million in 2021, then grew by 8.90% to $28.1 million in 2022, then increased by 0.62% to $28.3 million in 2023, then increased by 8.30% to $30.7 million in 2024.